2024-09-18 - Analysis Report
## Lilly (LLY) Stock Analysis

### Company Overview

Lilly (LLY) is a pharmaceutical company engaged in the research, development, manufacture, and marketing of pharmaceutical products. 

### Performance Analysis

**1. Return Comparison and Relative Outperformance:**

* **Cumulative Return:** 531.56% 
* **S&P 500 (VOO) Cumulative Return:** 88.56%
* **Return Difference:** 443.0%
* **Relative Outperformance:** 92.04% 

Lilly has significantly outperformed the S&P 500, with its cumulative return over 4 times higher. The relative outperformance of 92.04% indicates that LLY's performance has been in the top 92% of its historical range compared to the S&P 500.

**2. Recent Price Movements:**

* **Closing Price:** $905.34
* **5-Day Moving Average:** $921.7
* **20-Day Moving Average:** $934.97
* **60-Day Moving Average:** $897.78

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend. However, the 60-day moving average is significantly lower than the shorter-term moving averages, suggesting a potential support level at around $897.78.

**3. Technical Indicators:**

* **RSI:** 35.33 
* **PPO:** -0.58
* **Delta_Previous_Relative_Divergence:** -3.54 (Short-term bearish)
* **Expected Return:** 38.47% (Maximum expected return over 5 years for current invested amount)

The RSI suggests that the stock is currently in oversold territory. The negative PPO and the declining Relative Divergence indicate short-term bearish momentum. However, the high expected return suggests a potential for long-term growth.

**4. Recent Earnings and Outlook:**

| Date     | EPS    | Revenue |
| -------- | ------ | -------- |
| 2024-08-08 | 3.29  | 11.30 B$ |
| 2024-04-30 | 2.49  | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96  | 8.31 B$ |
| 2024-08-08 | 1.96  | 8.31 B$ |

Lilly's recent earnings have shown strong growth, exceeding expectations. The company's revenue has also been consistently increasing. However, the negative EPS in Q3 2023 highlights some challenges. The strong growth in recent quarters suggests a positive outlook for the company's future performance.

### Overall Analysis

Lilly is a strong performer with a history of outperforming the market. The current technical indicators suggest short-term bearish momentum, but the company's strong earnings and future prospects suggest potential for long-term growth. The stock is currently trading below its moving averages, offering a potential entry point for investors seeking long-term exposure to the pharmaceutical industry. However, investors should monitor the stock's price movements and technical indicators for any potential shifts in momentum.